Proactive Investors - Run By Investors For Investors

Allergy Therapeutics celebrating 20 years of growth and innovation

Allergy Therapeutics PLC's (LON:AGY) CEO Manuel Llobet and chief financial officer Nick Wykeman discuss with Proactive London's Andrew Scott the group's results for the six months to December 2018.

The company saw turnover rise 10.6% to £46.7mln in the period, up from £42.2mln a year earlier.

2019 is Allergy's 20th anniversary since they spun out of GlaxoSmithKline.

 
View full AGY profile View Profile

Allergy Therapeutics PLC Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use